A recent meta‐analysis about the diagnostic efficacy of CEA and CA15‐3 in patients with breast cancer revealed that higher plasma CEA and CA15‐3 are correlated with poor disease‐free survival and overall survival, and therefore, suggested that they might be evaluated anytime if possible.32 This evidence concerns the gene CEACAM5 and breast carcinoma.